Literature DB >> 28757383

Indications and outcome of splenectomy in hematologic disease.

S Bonnet1, A Guédon1, J-A Ribeil2, F Suarez3, J Tamburini4, S Gaujoux5.   

Abstract

Splenectomy is part of the therapeutic arsenal for benign or malignant hematological disorders that constitute the main indication for elective splenectomy. With the development of minimally invasive approaches, and in particular, laparoscopy, as well as the advent of monoclonal antibody therapy, the indications and the outcomes of splenectomy for hematologic disease have changed in recent years. Nonetheless, splenectomy has its place in hemoglobinopathies and hemolytic diseases, improves thrombocytopenia in refractory immune thrombocytopenic purpura, can reverse sequelae linked to voluminous splenomegaly secondary to myelofibrosis, or can be used for diagnostic purposes or for splenomegaly in lymphoproliferative syndromes.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Hematology; Hemolysis; Hypersplenism; Lymphoproliferative syndrome; Myeloproliferative syndrome; Splenectomy; Splenomegaly

Mesh:

Year:  2017        PMID: 28757383     DOI: 10.1016/j.jviscsurg.2017.06.011

Source DB:  PubMed          Journal:  J Visc Surg        ISSN: 1878-7886            Impact factor:   2.043


  10 in total

1.  Is preoperative anemia a significant risk factor for splenectomy patients? A NSQIP analysis.

Authors:  Alexandra Z Agathis; Prerna Khetan; Daniel Bitner; Celia M Divino
Journal:  Surg Open Sci       Date:  2020-05-14

2.  Indications and Outcomes of Splenectomy for Hematological Disorders.

Authors:  Rafiye Ciftciler; Aysel Pasayeva; Salih Aksu; Osman Ozcebe; Nilgun Sayınalp; Umit Yavuz Malkan; Yahya Buyukasık; Ibrahim C Haznedaroglu
Journal:  Open Med (Wars)       Date:  2019-06-17

3.  Allogeneic hematopoietic stem cell transplantation in a 3-year-old boy with congenital pyruvate kinase deficiency: A case report.

Authors:  Zhong-Yang Ma; Xue Yang
Journal:  World J Clin Cases       Date:  2021-04-26       Impact factor: 1.337

4.  The Correlation Between Surgical Procedures and Quality of Life Among Sickle Cell Disease Patients: A Perspective Saudi Study.

Authors:  Ali J Al Saad; Rayan A Buhalim; Faisal A Al Jabr; Abdulaziz M Al Dehailan; Abdulaziz A Albahrani
Journal:  Cureus       Date:  2022-01-18

5.  Splenectomy perspective for non-malignant hematological disorders: A cross-sectional study in the Eastern Province of KSA.

Authors:  Mortadah H Alsalman; Faisal A Al Jabr; Samma T Eraqe; Sayed I Ali; Abdallah Essa
Journal:  J Taibah Univ Med Sci       Date:  2022-03-08

6.  The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report.

Authors:  Giuseppe Auteri; Daniela Bartoletti; Clara Bertuzzi; Francesco Bacci; Valeria Tonini; Lucia Catani; Nicola Vianelli; Michele Cavo; Francesca Palandri
Journal:  Hematol Rep       Date:  2021-06-21

7.  Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes.

Authors:  Wilson M Alobuia; Kenneth Perrone; David J Iberri; Rondeep S Brar; David A Spain; Joseph D Forrester
Journal:  Surg Open Sci       Date:  2020-08-16

8.  The non-coding RNome after splenectomy.

Authors:  Mihnea P Dragomir; Stefan Tudor; Keishi Okubo; Masayoshi Shimizu; Meng Chen; Dana Elena Giza; William Ruixian He; Cristina Ivan; George A Calin; Catalin Vasilescu
Journal:  J Cell Mol Med       Date:  2019-09-08       Impact factor: 5.310

9.  The development of a quality improvement project to improve infection prevention and management in patients with asplenia or hyposplenia.

Authors:  Natalya Elizabeth O'Neill; Jillian Baker; Richard Ward; Colleen Johnson; Linda Taggart; Michelle Sholzberg
Journal:  BMJ Open Qual       Date:  2020-08

10.  18F-fluorodeoxyglucose positron emission tomography-based prediction for splenectomy in patients with suspected splenic lymphoma.

Authors:  Yingwei Hu; Weiyan Zhou; Siyuan Sun; Yihui Guan; Jiexian Ma; Yanhui Xie
Journal:  Ann Transl Med       Date:  2021-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.